drugset
drugset / Trial / NCT06623539

Efficacy and Safety of Pemafibrate for Nonalcoholic Fatty Liver Disease

NCT06623539 ↗

Phase 2 Active not recruiting 360 enrolled Yokohama City University
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a study to evaluate the effect of pemafibrate on fatty liver in patients with hypertgemia combined with NAFLD, using fenofibrate as a control.

Timeline

Start
2020-12-23
Primary completion
2025-06
Completion
2026-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Fenofibrate Small molecule 53.3 mg Oral
Subject K-877 Unknown 0.1 mg Oral
Subject K-877 Unknown 0.2 mg Oral

Indications

NAFLD1